Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine.
AUTOR(ES)
Bottiglieri, T
RESUMO
Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=488323Documentos Relacionados
- S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS
- The effect of methionine and S-adenosylmethionine on S-adenosylmethionine levels in the rat brain
- S-Adenosylmethionine Transport in Rickettsia prowazekii
- Transport of S-Adenosylmethionine in Saccharomyces cerevisiae
- Inhibition of leucine transport in Saccharomyces by S-adenosylmethionine.
